Results 41 to 50 of about 8,578 (238)

Cytotoxicity Effect of Quinoin, Type 1 Ribosome-Inactivating Protein from Quinoa Seeds, on Glioblastoma Cells

Toxins, 2021
Ribosome-inactivating proteins (RIPs) are found in several edible plants and are well characterized. Many studies highlight their use in cancer therapy, alone or as immunoconjugates, linked to monoclonal antibodies directed against target cancer cells ...
Rossella Rotondo, Sara Ragucci, Salvatore Castaldo, Maria Antonietta Oliva, Nicola Landi, Paolo V. Pedone, Antonietta Arcella, Antimo Di Maro   +7 more
doaj   +1 more source

Progress in immunoconjugate cancer therapeutics [PDF]

Cancer Cell, 2003
Advances in immunoconjugate technology have revitalized the "magic bullet" concept of immunotherapeutics for the treatment of cancer. The growing availability of "human" antibodies, the increased epitope repertoire due to genomics and proteomics efforts, and advances in the means of identification and production of tumor-specific antibodies have ...
openaire   +2 more sources

Synthesis and biodistribution of immunoconjugates of a human IgM and polymeric drug carriers [PDF]

, 1992
The synthesis and purification of radiolabelled immunoconjugates, composed of a human IgM monoclonal antibody directed against an intracellular tumour-associated antigen and either poly (alpha-L-glutamic acid) (PGA) or poly[N5-(2-hydroxyethyl)-L ...
Feijen, J., Loeffen, P., Hoes, C.J.T., Bos, E.S., Kaspersen, F., Grootoonk, J., Boon, P.J., Winters, M., Anderson, James M., Schlachter, I.   +9 more
core   +1 more source

Immunotoxins and Other Conjugates Containing Saporin-S6 for Cancer Therapy

Toxins, 2011
Ribosome-inactivating proteins (RIPs) are a family of plant toxins that permanently damage ribosomes and possibly other cellular substrates, thus causing cell death.
Andrea Bolognesi, Massimo Bortolotti, Manuela Pedrazzi, Letizia Polito   +3 more
doaj   +1 more source

UCNP-based Photoluminescent Nanomedicines for Targeted Imaging and Theranostics of Cancer

Molecules, 2020
Theranostic approach is currently among the fastest growing trends in cancer treatment. It implies the creation of multifunctional agents for simultaneous precise diagnosis and targeted impact on tumor cells.
Evgenii L. Guryev, Anita S. Smyshlyaeva, Natalia Y. Shilyagina, Evgeniya A. Sokolova, Samah Shanwar, Alexey B. Kostyuk, Alexander V. Lyubeshkin, Alexey A. Schulga, Elena V. Konovalova, Quan Lin, Indrajit Roy, Irina V. Balalaeva, Sergey M. Deyev, Andrei V. Zvyagin   +13 more
doaj   +1 more source

Design and Simple Assembly of Gold Nanostar Bioconjugates for Surface-Enhanced Raman Spectroscopy Immunoassays

Nanomaterials, 2019
Immunoassays using Surface-Enhanced Raman Spectroscopy are especially interesting on account not only of their increased sensitivity, but also due to its easy translation to point-of-care formats.
Maria João Oliveira, Miguel P. de Almeida, Daniela Nunes, Elvira Fortunato, Rodrigo Martins, Eulália Pereira, Hugh J. Byrne, Hugo Águas, Ricardo Franco   +8 more
doaj   +1 more source

Advancements in non-small cell lung cancer treatment: from early to advanced stages

Oncology in Clinical Practice
Over the past years, tremendous progress has been made in the treatment available for non-small cell lung cancer patients (NSCLC), both in the early and advanced stages of the disease.
Adam Płużański, Aleksandra Piórek
doaj   +1 more source

Preparation and characterization of immunoconjugates as an initial step for targeted alpha therapy [PDF]

, 2023
The basic principle of targeted alpha therapy (TAT) is that the alpha-emitting radionuclide is attached to specifically designed biomolecules, formulated as conjugates from antibodies, peptides and other small molecules. The design and characterization
Gaschet, Joëlle, Janevik-Ivanovska, Emilija, Maingueneau, Clémence, Guérard, François, Arev, Marija, Apostolova, Paulina   +5 more
core  

Herceptin-Geldanamycin Immunoconjugates [PDF]

Cancer Research, 2004
Abstract The efficacy of monoclonal antibodies (mAbs) as single agents in targeted cancer therapy has proven to be limited. Arming mAbs with a potent toxic drug could enhance their activity. Here we report that conjugating geldanamycin (GA) to the anti-HER2 mAb Herceptin improved the activity of Herceptin.
Raya Mandler, Hisataka Kobayashi, Ella R. Hinson, Martin W. Brechbiel, Thomas A. Waldmann   +4 more
openaire   +1 more source

Synthesis and biological evaluation of immunoconjugates of adriamycin and a human IgM linked by poly[N5-(2-hydroxyethyl)-l-glutamine [PDF]

, 1996
The synthesis and purification of radiolabelled immunoconjugates, composed of a human IgM monoclonal antibody (IgM 16.88) directed against an intracellular tumour-associated antigen, the drug carrier poly[N5-(2-hydroxyethyl)--glutamine] (PHEG) and the ...
Feijen, J., Hoes, C.J.T., E.S. Bos, Kaspersen, F., E. van der Struik, Grootoonk, J., Schlachter, I., van Doornmalen, A., M. Ankoné, J. Feijen, van der Struik, E., I. Schlachter, Pham, D., de Man, A., Boon, P.J., van Ettekoven, A., F. Kaspersen, P.J. Boon, A. de Man, Bos, E.S., D. Pham, C.J.T. Hoes, Ankoné, M., A. van Doornmalen, A. van Ettekoven, J. Grootoonk   +25 more
core   +1 more source